| Date Filed | Type | Description |
| 10/04/2023 |
4
| Lin Tai-An (Chief Scientific Officer) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 24,000 shares
@ $0
Granted 75,000 options to buy
@ $22.8, valued at
$1.7M
|
|
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2023 |
4
| Cassidy James (Chief Medical Officer) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 5,720 shares
@ $0 |
|
| 07/05/2023 |
4
| Smith L. Mary (Chief Development Officer) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 5,720 shares
@ $0 |
|
| 05/25/2023 |
4
| Schwartz Jeffrey Lawrence (Director) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 4,648 shares
@ $0
Granted 13,774 options to buy
@ $32.27, valued at
$444.5k
|
|
| 05/25/2023 |
4
| LYNCH DANIEL (Director) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 4,648 shares
@ $0
Granted 13,774 options to buy
@ $32.27, valued at
$444.5k
|
|
| 05/25/2023 |
4
| Lewis-Hall Freda C (Director) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 4,648 shares
@ $0
Granted 13,774 options to buy
@ $32.27, valued at
$444.5k
|
|
| 05/25/2023 |
4
| Hambleton Julie (Director) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 4,648 shares
@ $0
Granted 13,774 options to buy
@ $32.27, valued at
$444.5k
|
|
| 05/25/2023 |
4
| Fuhrman Alan (Director) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Granted 4,648 shares
@ $0
Granted 13,774 options to buy
@ $32.27, valued at
$444.5k
|
|
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/17/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 6.7% stake in SpringWorks Therapeutics, Inc. |
| 05/03/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/05/2023 |
4
| Ashar Bhavesh (Chief Commercial Officer) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,375 shares
@ $25.25, valued at
$34.7k
|
|
| 03/20/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/20/2023 |
4
| Schwartz Jeffrey Lawrence (Director) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Sold 1,750,000 shares
@ $28.5, valued at
$49.9M
|
|
| 03/16/2023 |
4
| Hambleton Julie (Director) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Sold 1,106 shares
@ $31.5021, valued at
$34.8k
|
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 4.2% stake in SpringWorks Therapeutics, Inc. |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in SPRINGWORKS THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 6.9% stake in SpringWorks Therapeutics Inc. |
| 02/07/2023 |
SC 13G
| BlackRock Inc. reports a 5.3% stake in SpringWorks Therapeutics, Inc. |
| 01/27/2023 |
4
| Pichl Daniel (Chief People Officer) has filed a Form 4 on SpringWorks Therapeutics, Inc.|
Txns:
| Sold 858 shares
@ $31, valued at
$26.6k
|
|
| 01/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|